Figure 11. Experimental validation of model gene and in vitro experiment with SEC61G knockdown. (A–G) Boxplots showing the differential expression of CCL20, MAP3K8, SEC61G, SLC34A2, CD79A, BIRC3, and RBM39 between tumor and normal tissues. (H) Survival curves showing the difference between SEC61G high and low expression groups. (I) Histogram shows the relative SEC61G expression between BEAS-2B, A549 and H1299. (J, K) After SEC61G knockdown, the cloning ability of A549 and H1299 cell lines decreased significantly.